|Mr. John F. Crowley||Chairman & CEO||1.96M||2.15M||1967|
|Mr. Bradley L. Campbell M.B.A.||Pres, COO & Director||899.2k||52.17k||1976|
|Ms. Daphne E. Quimi||Chief Financial Officer||630.45k||N/A||1966|
|Dr. Hung Viet Do||Chief Scientific Officer||637.43k||319.26k||1968|
|Ms. Ellen S. Rosenberg||Chief Legal Officer & Corp. Sec.||686.59k||N/A||1963|
|Ms. Samantha Prout||VP of Fin., Global Controller & Principal Accounting Officer||N/A||N/A||1978|
|Dr. Enrique DilonÃ©||Sr. VP of Technical Operations||N/A||N/A||1967|
|Andrew Faughnan||Director of Investor Relations||N/A||N/A||N/A|
|Mr. Patrik S. Florencio||Sr. VP, Global Chief Compliance & Risk Officer||N/A||N/A||N/A|
|Ms. Diana Moore||Head of Global Corp. Communications||N/A||N/A||N/A|
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Philadelphia, Pennsylvania.
Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of December 3, 2020 is 4. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 7; Compensation: 4.